Skip to main
NBP

NovaBridge Biosciences (NBP) Stock Forecast & Price Target

NovaBridge Biosciences (NBP) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NovaBridge Biosciences is poised for growth due to its innovative immuno-oncology pipeline containing three clinical stage programs and a core product, givastomig, with potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other gastrointestinal malignancies. The company's optionality program also adds potential upside to the current portfolio. With significant cash and short-term investments, NovaBridge is well-funded to support its operations through 2028 and the company's global expansion strategy and unique permission CLDN18.2 expression threshold bolsters confidence in its ability to develop and execute globally relevant clinical programs, making it an attractive investment opportunity.

Bears say

NovaBridge Biosciences is in a precarious position due to multiple risks to their product development and commercialization, including regulatory, clinical, financial, and intellectual property risks. Despite strong financials and an innovative pipeline, the projected price target of $9.00 may be difficult to achieve due to uncertainties in market adoption and competition, especially in the anti-VEGF market. Additionally, upcoming trials and data readouts will be critical in determining the potential success of their core product, givastomig, and the feasibility of reaching their projected price target.

NovaBridge Biosciences (NBP) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NovaBridge Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NovaBridge Biosciences (NBP) Forecast

Analysts have given NovaBridge Biosciences (NBP) a Strong Buy based on their latest research and market trends.

According to 1 analysts, NovaBridge Biosciences (NBP) has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NovaBridge Biosciences (NBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.